GeneDx Faces Securities Class Action Lawsuit Over Misleading Disclosures

The litigation, spearheaded by the DJS Law Group, centers on claims that GeneDx issued false and misleading statements to the market throughout the designated class period. The complaint highlights a significant decline in adjusted gross margins during the first quarter of 2026, alongside a subsequent downward revision of the company's full-year earnings projections. These events form the basis for allegations that the company failed to provide an accurate financial picture to its investors.

Shareholders seeking to participate in the legal action are not required to be appointed as lead plaintiffs to remain eligible for a potential recovery. The DJS Law Group, which specializes in securities litigation and corporate governance, is currently vetting claims from those who incurred losses due to the stock's performance. Interested parties can reach attorney David J. Schwartz at the firm’s Eastchester, New York, office to discuss the specific parameters of the case and their individual rights as stakeholders.